HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Anthony Good

Vice President Clinical Research

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551